FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034174856> ?p ?o ?g. }

• W2034174856 endingPage "1662" @default.
• W2034174856 startingPage "1656" @default.
• W2034174856 abstract "We report the outcomes of patients who had in-stent restenosis (IRS) that was treated with intravascular brachytherapy (IVBT) or sirolimus-eluting stent (SES) implantation. The benefit of IVBT for treating ISR is well documented. SES implantation decreases first-time ISR and, in preliminary reports, has been used to treat ISR. Fifty consecutive patients who had ISR were treated; the first 25 patients underwent SES implantation and the next 25 patients were treated with IVBT using a β-Cath System (a 40-mm strontium-90/yttrium-90 source). Quantitative angiographic and intravascular ultrasound follow-up were performed at 5.2 ± 1.1 and 12.1 ± 1.2 months; clinical follow-up was performed at 15 months. SES deployment and IVBT were successful in all patients. At 12-month follow-up, 8 patients who underwent IVBT had angiographic recurrence (4 in the stent and 4 at the stent edge); only 1 patient who underwent SES implantation developed recurrent ISR. At 12 months, in-stent late luminal loss was similar between the SES and IVBT groups (0.35 ± 0.45 vs 0.34 ± 0.46 mm, p = 0.9); however, in-stent net luminal gain was higher in the SES group than in the IVBT group (1.32 ± 0.13 vs 0.57 ± 0.19 mm, p <0.0001), and in-lesion late luminal loss was higher in the IVBT group (0.48 ± 0.32 vs 0.16 ± 0.42 mm, p = 0.004). At 12 months, intravascular ultrasound stent volume obstruction was higher after IVBT versus than after SES implantation (38.7% vs 6.7%, p <0.0001). At 15-month clinical follow-up, 64% and 96% (p <0.01) of patients who underwent IVBT and SES implantation, respectively, were free of major adverse cardiac events. In conclusion SES implantation for the treatment of ISR was effective and superior to catheter-based IVBT in preventing recurrent neointimal proliferation and angiographic restenosis at 1-year follow-up. We report the outcomes of patients who had in-stent restenosis (IRS) that was treated with intravascular brachytherapy (IVBT) or sirolimus-eluting stent (SES) implantation. The benefit of IVBT for treating ISR is well documented. SES implantation decreases first-time ISR and, in preliminary reports, has been used to treat ISR. Fifty consecutive patients who had ISR were treated; the first 25 patients underwent SES implantation and the next 25 patients were treated with IVBT using a β-Cath System (a 40-mm strontium-90/yttrium-90 source). Quantitative angiographic and intravascular ultrasound follow-up were performed at 5.2 ± 1.1 and 12.1 ± 1.2 months; clinical follow-up was performed at 15 months. SES deployment and IVBT were successful in all patients. At 12-month follow-up, 8 patients who underwent IVBT had angiographic recurrence (4 in the stent and 4 at the stent edge); only 1 patient who underwent SES implantation developed recurrent ISR. At 12 months, in-stent late luminal loss was similar between the SES and IVBT groups (0.35 ± 0.45 vs 0.34 ± 0.46 mm, p = 0.9); however, in-stent net luminal gain was higher in the SES group than in the IVBT group (1.32 ± 0.13 vs 0.57 ± 0.19 mm, p <0.0001), and in-lesion late luminal loss was higher in the IVBT group (0.48 ± 0.32 vs 0.16 ± 0.42 mm, p = 0.004). At 12 months, intravascular ultrasound stent volume obstruction was higher after IVBT versus than after SES implantation (38.7% vs 6.7%, p <0.0001). At 15-month clinical follow-up, 64% and 96% (p <0.01) of patients who underwent IVBT and SES implantation, respectively, were free of major adverse cardiac events. In conclusion SES implantation for the treatment of ISR was effective and superior to catheter-based IVBT in preventing recurrent neointimal proliferation and angiographic restenosis at 1-year follow-up." @default.
• W2034174856 created "2016-06-24" @default.
• W2034174856 creator A5002494776 @default.
• W2034174856 creator A5002654097 @default.
• W2034174856 creator A5003318315 @default.
• W2034174856 creator A5005627641 @default.
• W2034174856 creator A5020350844 @default.
• W2034174856 creator A5021683949 @default.
• W2034174856 creator A5031007248 @default.
• W2034174856 creator A5035989292 @default.
• W2034174856 creator A5039747556 @default.
• W2034174856 creator A5043338374 @default.
• W2034174856 creator A5044220449 @default.
• W2034174856 creator A5046043143 @default.
• W2034174856 creator A5053894893 @default.
• W2034174856 creator A5055057046 @default.
• W2034174856 creator A5075854254 @default.
• W2034174856 creator A5076090927 @default.
• W2034174856 creator A5088300730 @default.
• W2034174856 date "2005-12-01" @default.
• W2034174856 modified "2023-10-05" @default.
• W2034174856 title "Comparison Between Sirolimus-Eluting Stents and Intracoronary Catheter-Based Beta Radiation for the Treatment of In-Stent Restenosis" @default.
• W2034174856 cites W1605950868 @default.
• W2034174856 cites W1968838853 @default.
• W2034174856 cites W1985567774 @default.
• W2034174856 cites W1989919813 @default.
• W2034174856 cites W1998004031 @default.
• W2034174856 cites W2017888073 @default.
• W2034174856 cites W2020906145 @default.
• W2034174856 cites W2025987337 @default.
• W2034174856 cites W2026168678 @default.
• W2034174856 cites W2031977914 @default.
• W2034174856 cites W2032903984 @default.
• W2034174856 cites W2076552301 @default.
• W2034174856 cites W2079818105 @default.
• W2034174856 cites W2083630382 @default.
• W2034174856 cites W2094303781 @default.
• W2034174856 cites W2096487230 @default.
• W2034174856 cites W2104513370 @default.
• W2034174856 cites W2105174074 @default.
• W2034174856 cites W2109550616 @default.
• W2034174856 cites W2111592624 @default.
• W2034174856 cites W2119951407 @default.
• W2034174856 cites W2133131432 @default.
• W2034174856 cites W2137420009 @default.
• W2034174856 cites W2146665526 @default.
• W2034174856 cites W2163780498 @default.
• W2034174856 cites W2167351939 @default.
• W2034174856 cites W2324489407 @default.
• W2034174856 cites W2152294132 @default.
• W2034174856 doi "https://doi.org/10.1016/j.amjcard.2005.07.081" @default.
• W2034174856 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16360353" @default.
• W2034174856 hasPublicationYear "2005" @default.
• W2034174856 type Work @default.
• W2034174856 sameAs 2034174856 @default.
• W2034174856 citedByCount "26" @default.
• W2034174856 countsByYear W20341748562012 @default.
• W2034174856 countsByYear W20341748562013 @default.
• W2034174856 countsByYear W20341748562014 @default.
• W2034174856 countsByYear W20341748562021 @default.
• W2034174856 crossrefType "journal-article" @default.
• W2034174856 hasAuthorship W2034174856A5002494776 @default.
• W2034174856 hasAuthorship W2034174856A5002654097 @default.
• W2034174856 hasAuthorship W2034174856A5003318315 @default.
• W2034174856 hasAuthorship W2034174856A5005627641 @default.
• W2034174856 hasAuthorship W2034174856A5020350844 @default.
• W2034174856 hasAuthorship W2034174856A5021683949 @default.
• W2034174856 hasAuthorship W2034174856A5031007248 @default.
• W2034174856 hasAuthorship W2034174856A5035989292 @default.
• W2034174856 hasAuthorship W2034174856A5039747556 @default.
• W2034174856 hasAuthorship W2034174856A5043338374 @default.
• W2034174856 hasAuthorship W2034174856A5044220449 @default.
• W2034174856 hasAuthorship W2034174856A5046043143 @default.
• W2034174856 hasAuthorship W2034174856A5053894893 @default.
• W2034174856 hasAuthorship W2034174856A5055057046 @default.
• W2034174856 hasAuthorship W2034174856A5075854254 @default.
• W2034174856 hasAuthorship W2034174856A5076090927 @default.
• W2034174856 hasAuthorship W2034174856A5088300730 @default.
• W2034174856 hasConcept C126838900 @default.
• W2034174856 hasConcept C141071460 @default.
• W2034174856 hasConcept C164705383 @default.
• W2034174856 hasConcept C2776931568 @default.
• W2034174856 hasConcept C2777921159 @default.
• W2034174856 hasConcept C2778283817 @default.
• W2034174856 hasConcept C2778583881 @default.
• W2034174856 hasConcept C71924100 @default.
• W2034174856 hasConceptScore W2034174856C126838900 @default.
• W2034174856 hasConceptScore W2034174856C141071460 @default.
• W2034174856 hasConceptScore W2034174856C164705383 @default.
• W2034174856 hasConceptScore W2034174856C2776931568 @default.
• W2034174856 hasConceptScore W2034174856C2777921159 @default.
• W2034174856 hasConceptScore W2034174856C2778283817 @default.
• W2034174856 hasConceptScore W2034174856C2778583881 @default.
• W2034174856 hasConceptScore W2034174856C71924100 @default.
• W2034174856 hasIssue "12" @default.
• W2034174856 hasLocation W20341748561 @default.
• W2034174856 hasLocation W20341748562 @default.
• W2034174856 hasOpenAccess W2034174856 @default.

• next